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Abstract
The nonclassic class I human leukocyte antigen E (HLA-E) molecule engages the inhibitory NKG2A receptor on sev-
eral cytotoxic effectors, including natural killer (NK) cells. Its tissue distribution was claimed to be wider in normal than
in neoplastic tissues, and surface HLA-E was undetectable in most tumor cell lines. Herein, these issues were re-
investigated taking advantage of HLA-E–specific antibodies, immunohistochemistry, and biochemical methods de-
tecting intracellular and surface HLA-E regardless of conformation. Contrary to published evidence, HLA-E was
detected in a few normal epithelia and in a large fraction (approximately 1/3) of solid tumors, including those derived
from HLA-E–negative/low-normal counterparts. Remarkably, HLA-E was detected in 30 of 30 tumor cell lines repre-
sentative of major lymphoid and nonlymphoid lineages, and in 11 of 11, it was surface-expressed, although in a con-
formation poorly reactive with commonly used antibodies. Coexpression of HLA-E and HLA class I ligand donors was
not required for surface expression but was associated with NKG2A-mediated protection from lysis by the cytotoxic
cell line NKL and polyclonal NK cells from healthy donors, as demonstrated by antibody-mediated relief of protection
in 10% to 20% of the tested target-effector combinations. NKG2A-mediated protection of additional targets became
evident on NK effector blocking with antibodies to activating receptors (DNAM-1, natural cytotoxicity receptors, and
NKG2D). Thus, initial evidence that the long-elusive HLA-E molecule is enhanced by malignant transformation and is
functional in tumor cells is presented here, although its importance and precise functional role remain to be addressed
in the context of a general understanding of the NK ligand–receptor network.
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Introduction
Human leukocyte antigen E (HLA-E) is a nonclassic class I molecule
recognized by natural killer (NK) cells, CD8 cytotoxic T lymphocytes
(CTLs), and a more recently described subset of CD8 effectors with
memory phenotype, called by some authors NK-CTLs [1–4]. NK cells
and certain CTL subsets engage cell surface HLA-E through hetero-
dimeric lectin-like receptors, both inhibitory (CD94/NKG2A) and
activating (i.e., CD94/NKG2C). NK-CTLs primarily engage HLA-E
through (oligo)clonally rearranged T-cell receptor (TcR) and lyse target
cells, but they may also express NKG2A [1–4].
Inhibition through NKG2A is possibly the most thoroughly under-
stood function of HLA-E. It requires the stabilization of the HLA-E
heavy chain through association with its light-chain subunit (β2m)
and short peptide ligands cleaved from the signal sequences of “permis-
sive” class I alleles (the classic HLA-A, -B, and -C and the nonclassic
HLA-G heavy chains), with the aid of class I–dedicated chaperones
such as TAP and tapasin (reviewed in Rodgers and Cook [5]).
Coexpression of HLA-E and permissive alleles, crucial to this mecha-
nism of ligand donation/stabilization, is thought to protect the con-
ceptus from a maternal hemiallogeneic response [6] and prevent the
inappropriate recognition of somatic self [7], but HLA-Emay also favor
immunoevasion. For instance, some viral genomes encode proteins
acting as surrogate donors of HLA-E ligands [8,9], and ovarian carci-
noma cells were shown to express increased levels of the ligand donor
HLA-G as a result of interferon γ (IFN-γ) treatment [10]. However,
because IFN-γ also upregulates antigen-presenting HLA-A, -B, and -C
molecules, that is, a full set of major activating T-cell ligands, it is diffi-
cult to predict the final outcome (evasion or tumor control) in this and
in similar [11] situations.
Unfortunately, the critical issue of whether HLA-E levels differ be-
tween normal and neoplastic tissues remains largely not addressed.
For instance, immunohistochemistry detected HLA-E at several extra-
placental locations, including normal white blood cells, liver, skin, and
lung, but the reactive cell types were not specified [12]. Expression
in the skin was subsequently confirmed [11], and HLA-E was also de-
tected in certain endothelia but not in the few tested glandular epithelia
[13]. As to biochemistry and flow cytometry studies, the commonly
used 3D12 and MEM antibodies detected HLA-E polypeptides in
the soluble extracts and/or on the surface of only 10 of 37 [14] and
4 of 31 [15] tumor cell lines. To complicate interpretations, HLA-E
transcripts could be detected in the absence of HLA-E polypeptides
[15], and HLA-E polypeptides were detected at an intracellular loca-
tion but not on the cell surface [11].
On the basis of the available data, one might conclude that HLA-E is
expressed in an undefined, possibly wide, range of normal tissues, but
only in a few tumor cells in culture, either constitutively (seldom) or
(possiblymore often) following IFN-γ treatment, providing a weak ratio-
nale to investigate its function in tumor cells. Possibly for this reason,
there are, to our knowledge, few published studies on this topic [11,16].
A more recent study of ours may help to reinterpret some of these
results. In this study [17], it was shown that 3D12 and the MEM
antibodies [11,13–15,18] selectively bind a subpopulation of unfolded
HLA-E molecules free of β2m, whereas biochemical approaches,
among which the most effective is a reverse biotin labeling method,
detect surface HLA-E regardless of conformation.
Using the HLA-E–specific [17] MEM-E02 antibody, we report
herein the tissue distribution of HLA-E in normal nonlymphoid tissues
and their malignant counterparts. Through biotin labeling and cyto-
toxicity assays, we measure surface HLA-E expression and assess for
the first time the NK-inhibitory function of HLA-E constitutively
expressed under the control of its own promoter in untransfected neo-
plastic cell lines, in the presence and absence of permissive alleles.
The findings reported herein reconcile previous conflicting results,




Neoplastic tissues from patients (free from therapy) undergoing
surgery were obtained upon written consent following the recommen-
dations of the latest (March 1, 2006) Regina Elena Institute Ethical
Committee Official Guideline. For further details, see Supplemental
Materials and Methods.
Cell Lines
The 221B lymphoblastoid cell line and its transfectants, namely,
221.AEH [19], 221.G1, 221.B15 [20], and 221.B*0702 [21], were
obtained through the courtesy of different investigators and/or the col-
laborative efforts of the HLA-G and -E Workshops (see acknowledg-
ments). Epstein-Barr virus–immortalized B lymphocytes (EBV-B) and
tumor cell lines are listed in the Supplemental Materials and Methods
along with their HLA-A, -B, and -C typing. Some of these are early
passage (<10 subcultures) tumor cells previously established [22]. Nor-
mal human epidermal melanocytes (NHEMs) were purchased from
Lonza (Walkersville, MD). HLA-E genotyping was obtained by direct
sequencing of genomic DNA, as described [17].
Biochemical Methods
The mouse monoclonal antibodies MEM-E/02, MEM-E/06,
MEM-E/07, and MEM-E/08 [13,17,18] are all from Exbio, Prague,
Czech Republic; 3D12, 4D12 [14,23], W6/32 [24], Namb-1 [25], L31
[26], and a polyclonal to ERp57 were used in previous publications
of ours [22,26–29]. The reverse surface biotin labeling method is
described [17].
Flow Cytometry
Tumor cells and peripheral blood mononuclear cells (PBMCs)/
purified NK cells were stained on ice with either fluorochrome-labeled
antibodies or with a predetermined optimal (10 μg/ml) concentration
of primary antibody/chimeric immunoglobulin (Ig). In the latter case,
primary antibody binding was revealed by fluorescence isothiocyanate–
labeled rabbit antibodies to either mouse or human Ig (Dako, Glostrup,
Denmark). Isotype-matched control antibodies, or a chimeric Ig of
irrelevant specificity, were included as negative controls. Specifically
bound fluorescence was immediately analyzed without fixation by a
FACScan flow cytometer (Becton, Dickinson & Co, Mountain View,
CA). Antibodies toMICA (159227),MICB (MAB), ULBP1 (170818),
ULBP2 (165903), ULBP3 (166510), NKG2A (131411), NKG2C
(134591), NKG2D (149810), DNAX accessory molecule 1 (DNAM-
1/CD226) (102511), NKp30 (210845), NKp44 (253415), NKp46/
CD335 (195314), and recombinant human Fc chimeras to activating
immune receptors DNAM-1-Fc, NKp30-Fc, NKp44-Fc, and NKp46-
Fc were from R&D Systems (Minneapolis, MN). SKII.4 to polyo-
virus receptor (CD155) was from Dr Marco Colonna. Antibody to
Nectin-2 was from BD Pharmingen (San Jose, CA). Antibodies to
CD3 (UCHT1) and CD56 (MOC-1) were from Dako. Antibodies
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to killer Ig-like receptor (KIR) KIR2DL2/DL3 (DX27), KIR3DL1
(DX9), and KIR2DL1/DS1 (11PB6) were fromMiltenyi Biotec GmbH
(Bergisch Gladbach, Germany). Antibodies to Ig-like transcript (ILT)
ILT2 (GHI/75) were from Biolegend (San Diego, CA).
NK Cell–Mediated Cytotoxicity
The continuous NK cell line NKL [30] expresses NKG2A and ILT2
[31]. Polyclonal NK cells (typically 60% to 75% CD56+/CD3−, and
60% to 80% NKG2A+) were established by culturing healthy donor
PBMCs in vitro for 10 to 12 days on feeder layers of RPMI 8866 cells,
as described [32]. They were further purified (>98% CD56+/CD3−) by
negative immunomagnetic selection (Miltenyi). Cytotoxicity was mea-
sured by a standard 4-hour 51Cr release assay, at the indicated effector-
target (E/T) ratios, using as targets 5 × 103 cells per microplate well in
triplicate. Antibodies (10 μg/ml) or Ig fragment antigen binding 2 frag-
ments (7.5 μg/ml) to HLA molecules and NK cells were separately in-
cubated at room temperature for 15 minutes with target and effector
cells, respectively, before dispensing into the 96-well microplate.
Results
Tissue Distribution of HLA-E in Normal Adult Tissues and
Neoplastic Lesions
Immunohistochemical staining with MEM-E/02 gave a fine ground-
glass pattern sparing the nuclei in a few normal tissues (Figure 1,A-C , and
Table W1) and in a much wider spectrum of tumor lesions (Figure 1,
D-F ). Frequency and intensities of positive reactions were different in
different histotypes (Table W2). For instance, ovarian and testicular
tumors, non–small cell lung carcinomas, soft tissue tumors (Figure 1D),
as well as cutaneous melanoma (Figure 1F ), most of which derive from
a tested counterpart in which HLA-E was undetectable, displayed from
intermediate to high frequencies of MEM-E/02 reactivity. Unlike endo-
thelia from normal tissues, some tumor endothelia were clearly reactive
(Figure 1C). HLA-E down-regulation was exclusively observed in 50%
approximately of endometrial carcinoma lesions (Table W2; Figure 1E
displays a positive case). In summary, one third of the tumor lesions were
stained by MEM-E/02, most often because enhancement or de novo
appearance associated with malignant transformation.
Widespread Accumulation and Surface Expression of HLA-E
Polypeptides in Tumor Cells
Western blot analysis with MEM-E/02 of 24 tumor cell lines from
representative lineages (Figure W1) detected HLA-E polypeptides of
the correct 42-kDa size at extremely variable levels. All the tumor cells
were clearly positive, including the K562 cell line that was found to ex-
press the lowest HLA-E levels, only detectable on long filter exposure
(see below).
Next, 33 tumor cell lines were assayed by flow cytometry with the
HLA-E–restricted MEM-E/02, MEM-E/06, MEM-E/07, and MEM-E/
08 antibodies, and 15 were also tested with the 3D12 and 4D12 anti-
bodies. Although four of these cells (U937, Jurkat, Raji, and K562) had
previously been shown to differ in 3D12 surface binding [14], all the
antibodies including 3D12 and 4D12 gave a dull fluorescence pattern
in our hands, with differences among antibodies and cell lines being
too small to represent a reliable ranking method (representative results
are shown in Figure W2 and Table W3).
To detect surface HLA-E molecules regardless of antibody reactivity,
11 tumor cell lines and two cultures of NHEMs (NHEM1 and
NHEM2) were assessed for surface HLA-E expression by reverse bio-
tin labeling [17]. Because there are two nonsynonymous HLA-E alleles
[33] with high (HLA-E107G) and low (HLA-E107R) surface expression
[34], all the cells were HLA-E typed.
As opposed to the similar, dull staining detected by flow cytome-
try, biotin labeling (Figure 2A) detected widely different levels of sur-
face HLA-E. Cells lacking coexpression of permissive alleles (221,
Figure 1. Immunohistochemical analysis of HLA-E. Normal (A-C) and neoplastic (D-F) nonlymphoid human tissues were stained with
MEM-E/02 and nuclear counterstained with Mayer hematoxylin. A ground-glass pattern was detected in the principal but not the basal
cells in the epididymis (A, arrows), in endometrial cells (B, arrows), and in the vascular endothelium of the myometrium (C, arrows). In
tumors, variable expression was seen in a case of osteosarcoma (D), a well-differentiated endometrial carcinoma (E), and an in transit
metastatic melanoma (F). Original magnifications, ×160 (A-C, E); ×250 (D and F). Scale bars, 100 μm.
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K562, and the 221.B15 transfectant) only expressed immature (Endo
H–sensitive) glycoforms (lanes 1-2, 39-40, and 43-44), as described
[17]. In contrast, U937, Raji, Jurkat, WI-L2, JY, FO-1-β2m, SK-
MEL-37, A431, and NHEM2 cells expressing detectable levels of
HC10-reactive class I molecules (lanes 15-20, 53-54, 88-93, 125-126,
and 148-149), namely, potential donors of HLA-E ligands, expressed
both mature (Endo H–insensitive) and immature (Endo H–sensitive)
HLA-E glycoforms (lanes 3-8, 41-42, 75-80, 116-117, and 139-140).
NHEM1 melanocytes and MCF7 cells were the only exceptions, in
that the former did react with HC10 (lanes 150-151) but only ex-
pressed immature glycoforms (lanes 141-142), whereas the latter reacted
barely, if at all, with HC10 (lanes 123-124) but did express some ma-
ture HLA-E glycoforms (lanes 114-115). Endo H–sensitivity of surface
HLA-E was not due to biotin labeling of intracellular class I heavy chains
because HC10-reactive heavy chains recovered from the same soluble
extracts were insensitive to Endo H digestion (lanes 16, 18, 20, 54,
56, 89, 91, 93, 126, 149, and 151), as expected.
In summary, all the cells were positive and could be ranked by
densitometry according to the expression of the two surface HLA-E
glycoforms (Figure 2B). Reminiscent of immunohistochemistry (see
previous paragraph), normal cells (melanocytes) clustered at the low
end of the rank, whereas tumor cell lines were distributed across the
whole range of HLA-E levels. HLA-E levels showed no obvious corre-
lation with either HLA-E typing or coexpression with ligand donors.
For instance, 221 and K562 cells both lack permissive alleles but lie
at the opposite ends of the rank, and none of the HC10-reactive cell
lines expressed as much HLA-E as 221.
Finally, widespread expression of HLA-E is not an artifact of in vitro
passaging because reverse biotin-labeling confirmed its presence on
the surface of three early passage (<10 subcultures) tumor cell lines
(Figure W3).
Surface HLA-E and Lysis by the Cytotoxic Cell Line NKL
Because biotin labeling revealed surface HLA-E molecules on 221
and K562 cells, previously described to be unreactive with antibodies
to HLA-E [14,15,19], we wanted to rule out a low-level baseline
NKG2A-mediated protection that may have gone unnoticed in pre-
vious studies [12,31]. To this end, two experiments were performed
in which 221 and K562 cells were tested as targets of the widely used
NK cytotoxic cell line NKL.
In the first experiment (Figure W4), whole Ig and Ig fragment anti-
gen binding 2 fragments of W6/32 (to HLA-E and most class I HLA
molecules) and Z199 (to NKG2A) did not appreciably affect NKL
lysis of parental 221 cells, but they efficiently restored, as expected,
lysis of 221.AEH cells expressing a hybrid HLA-E molecule (AEH)
capable of self ligand donation [19].
In the second experiment, 221 and K562 cells were treated with
IFN-γ, a potent enhancer of class I expression also capable of modifying
Figure 2. HLA-E expression on the tumor cell surface. (A) NP40 extracts (1 mg) from biotin-labeled cells were immunoprecipitated by
streptavidin-conjugated beads and either digested with Endoglycosidase H [41] or mock-incubated. Surface proteins were resolved by
SDS-PAGE, electroblotted, and identified by sequential staining/stripping of the filters with the indicated antibodies. Extracts from biotin-
labeled cells (100 μg) were also run side by side. Arrowheads mark residual staining by MEM-E/02 not removed by stripping. Five ex-
periments are shown, each including 221 cells as an internal control. Each cell line was tested at least twice with similar results, except
FO-1-β2m cells in which HLA-E expression was slightly underestimated in the experiment shown in the figure, as assessed by two additional
experiments. (B) Values of densitometric scans of the Endo H–resistant and Endo H–sensitive HLA-E bands from lanes 2, 4, 6, 8, 40, 42, 76,
78, 80, 115, and 117, sorted by intensity. HLA-E typing, shown in parentheses, was either reported previously [14,15] or assessed by direct
DNA sequencing as described [17]. G indicates HLA-E107G; R, HLA-E107R; RG, heterozygous condition.
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the pool of peptide ligands generated by the proteasome [35]. Flow
cytometry with antibodies to conformed HLA class I molecules (W6/
32) and β2m (Namb-1) revealed slight (in 221) and drastic (in K562)
increases in surface class I expression (Figure 3A). These increases were
in agreement with those detected by surface biotin labeling (Figure 3B,
lanes 1-8), conclusively demonstrating IFN-γ–dependent surface en-
hancement of HLA-E in these cells. However, NKL-mediated lysis re-
mained unaffected by IFN-γ over a wide range of E/T ratios (Figure 3C).
Altogether, these results (Figures 2, 3, and W4) demonstrate that
surface-expressed HLA-E does not appreciably protect 221 and K562
cells from NKL lysis.
Next, we looked for a protective effect ofHLA-E coexpressedwith vari-
able levels of its ligand donors. NKL cells were used as cytolytic effectors
on 11 tumor cell lines (Jurkat, WI-L2, Raji, U937, M10, MNT-1, SK-
MEL-37, SK-MEL-93, FO-1-β2m, A431, and MCF7). In these cells,
HLA-A, -B, and -C molecules are expected to contribute peptide ligands
enabling HLA-E inhibition through NKG2A and, in addition, to act as
direct inhibitory ligands of the KIR and ILT2 receptors. Because they
express ILT2 and NKG2A, but not KIR ([31] and our own unpublished
data), NKL cells provide a simplified readout for NK lysis.
As expected, the 11 target tumor cell lines were lysed to a differ-
ent extent. FO-1-β2m cells were consistently most sensitive to lysis
Figure 3. Up-regulation of HLA-E heavy chains by IFN-γ and NKL lysis. (A) 221 and K562 cells, either untreated or treated for 72 hours with
200 U/ml of recombinant IFN-γ, were tested by flow cytometry with antibodies to class I heavy chains (W6/32) and β2m (Namb-1). An
antibody to HLA class II molecules (KUL/05) was used as a control for IFN-γ responsiveness of 221 cells. (B) Control and IFN-γ–treated
(as previously mentioned) 221 and K562 cells were surface-labeled with biotin and HLA-E was revealed as described in the legend to
Figure 2. (C) Control and IFN-γ–treated (as previously mentioned) 221 and K562 cells were tested for their susceptibility to NKL lysis at
the indicated E/T ratios. The experiment was repeated three times.
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(representative results shown in Figure W5) and displayed the largest
repertoire of activating NK ligands among the five selected cell lines
(Table W4). No other obvious correlations were apparent between sus-
ceptibility to lysis and expression of NK ligands, including HLA-E.
For instance, FO-1-β2m, A431, and U937 cells were lysed to a differ-
ent extent (Figure 4) in spite they express similar (intermediate) surface
HLA-E levels (compared with Figure 2B). As also shown by repre-
sentative results in Figure W5, NKL lysis of 7 of 11 cell lines was un-
affected by antibodies to ILT2 (GHI/75) and NKG2A (Z199), but
GHI/75 enhanced lysis in the remaining 4 cell lines (FO-1-β2m, A431,
M10, and SK-Mel 37), 2 of which (FO-1-β2m and A431) became
more susceptible on incubation with antibodies to NKG2A. We con-
clude that a fraction of tumor targets can be demonstrated to be pro-
tected through ILT2 and, possibly to a lesser extent, through NKG2A.
Surface HLA-E and Lysis by Polyclonal NK Cells
One may wonder whether the role of the HLA-E/NKG2A axis
might be similarly appreciated using a panel of nonimmortalized effec-
tor NK cells. Polyclonal NK cells (>98% CD56+/CD3−) were then
obtained by immunomagnetic sorting from the PBMCs of six differ-
ent healthy donors cultured on feeder layers without interleukin 2, as
described [32]. Like NKL, these NK cell populations expressed high
levels of inhibitory receptors, not only NKG2A, NKG2D, and ILT2
but also KIRs, and in addition they also expressed activating recep-
tors such as DNAM-1 and the natural cytotoxicity receptors (NCRs)
NKp30, NKp44, and NKp46 (for additional details, see Figure W6).
Polyclonal NK cells were used as effectors in a cytotoxicity assay using as
targets the immortalized JY B lymphoid line and nine tumor cell lines
(Jurkat, WI-L2, Raji, U937, SK-MEL-37, SK-MEL-93, FO-1-β2m,
A431, and MCF7). The protective role of NKG2A from NK lysis was
assessed as previously mentioned in the presence of the NKG2A-specific
antibody Z199.
NKG2A-mediated protection (i.e., protection in donor 1:JY and
donor 3:A431 but not in donor 3:MCF7; Figure 4A) was detected in
a minority of E/T combinations. A complete synopsis is provided in
Figure 4B in which the highest E/T ratios are shown for simplicity.
Altogether, NKG2A-mediated protection was observed in 7 (23% ap-
proximately) of 27 cases (see connecting bars). As expected, six distinct
patterns were observed, that is, the six polyclonal NK cell populations
differed from one another and from NKL cells in their ability to kill a
given target and to display NKG2A-mediated protection. Overall, four
of six NK cell cultures could be demonstrated to be inhibited through
NKG2A with at least one target. Similar experiments performed with
bulk NK cells (not submitted to immunomagnetic purification) from
four donors resulted in 5 (11% approximately) of 44 Z199-mediated
lysis enhancements (not shown).
Functional Role of NKG2A in the Context of Activating
NK Cell Circuitry
In the attempt to account for the low percentage of E/T combinations
in which the inhibitory role of NKG2A is appreciable, we hypothesized
that a strong overriding activation might obscure NKG2A-mediated
inhibition. To obtain evidence in favor of this hypothesis, a panel of
three long-term (FO-1-β2m, SK-MEL-37, and A431) and four early
passage (Mel20, Br7, End7, and Ova7) tumor cell lines expressing one
or more major NK-activating ligands (Table W4) were tested in cyto-
toxicity as targets of polyclonal NK cells from three distinct donors ex-
pressing essentially all the cognate activating receptors (Figure W6).
Figure 4. Cytotoxic activity of polyclonal NK cells against tumor cells. (A) CD56+/CD3− effector cells were tested in a 51Cr release assay,
in the presence of antibodies to CD56 (C218) and to NKG2A (Z199) on the indicated targets. (B) Summary of cytotoxicity results (at an E/T
ratio of 20:1) with NK cells from 6 donors and 10 tumor cell targets in presence of either C218 (−) or Z199 (+). A line connects statis-
tically significant lytic enhancements by Z199, that is, differences in average values of triplicates more than three times the SD.
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Z199-mediated lysis enhancement was assessed not only in the absence
but also in the presence of mixtures of antibodies blocking those activat-
ing receptors known to bind the triggering ligands detectable (TableW4)
on the target.
Representative results (Figure 5) confirmed that Z199 by itself en-
hances NK lysis in a minority (5/21) of E/T combinations, but on
blocking of activating receptors and the consequent reduction in NK
lysis (observed in 14/21 E/T combinations), antibodies to NKG2A
become capable of restoring susceptibility to lysis of three additional
targets. It may be concluded that overriding activation (by DNAM-1
and/or NCR and/or NKG2D) may prevent appreciation of the in-
hibitory HLA-E/NKG2A axis.
Discussion
Consistent with their primary and specialized role at the fetal-maternal
interface, the expression of several nonclassic class I HLA molecules
is believed to be highly restricted [5,6]. The extensive immunohisto-
chemical testing performed herein is consistent with this view and, in
addition, shows that the few normal epithelia and tissues that constitu-
tively express HLA-E are from the genitourinary/reproductive tract and
the colonic mucosa. Perhaps, HLA-E contributes to safeguarding
somatic self integrity in these normal tissues.
In contrast, HLA-E expression is wider than previously appreciated
in malignant tissues, one third of which (including those derived from
an HLA-E–negative counterpart) are reactive with MEM-E/02 (Fig-
ure 1 and Tables W1 and W2). Herein, we present evidence support-
ing a functional role of HLA-E expression in tumors.
Widespread Surface Expression of HLA-E in Tumor Cells:
Comparison with Previous Studies
Two previous flow cytometry studies with either 4D12 or MEM
antibodies detected weak surface expression of HLA-E in a minority
of tumor cell lines [14,15]. In our hands, however, the same anti-
bodies resulted in a dull and substantially invariant surface fluorescence
pattern on 33 tumor cell lines, 11 of which also tested in the two pre-
viously mentioned studies (Figures W2 and 3 and Table W3). Only
by reverse biotin labeling (Figures 2 and 3) were we able to semi-
quantitatively detect a wide range of HLA-E levels. HLA-E was in-
variably surface-expressed under the species of two distinct glycoforms.
Surprisingly, tumor cells previously [14] ranked by flow cytometry
in the order U937 > Jurkat > Raji and K562 (Raji and K562 both
negative) were ranked by reverse biotin labeling in the order Raji ≅
Jurkat >> U937 > K562 (all positive), regardless of the glycoform
being considered.
A detailed comparison among flow cytometry studies is difficult
because few staining profiles are published, and/or the results are
charted on the basis of semiquantitative, subjective evaluation scales.
Regardless of protocols and interpretations, it may be concluded that
HLA-E molecules, although poorly reactive (at least in our hands)
with the available antibodies, are invariably present on the surface
of tumor cell lines.
HLA-E Contributes to Protect Tumors from NK Cell Lysis
As a first step to assess the function of HLA-E on tumor cells, so
far supported by limited evidence [10,16], we focused on its well-
known ability to protect from NK cell lysis through NKG2A ex-
pressed by the cytotoxic cell line NKL and resting polyclonal NK
cells from healthy donors. Specific antibodies to NKG2A relieved
protection in the case of some tumor cell lines coexpressing permis-
sive alleles but not in the case of parental 221 (B lymphoblastoid)
and K562 (erythromyeloid) cells lacking permissive alleles (Figures 3–
5 and W3). We conclude that surface HLA-E molecules are func-
tional in at least some tumor cell lines but not in 221 and K562 despite
that these cells do express HLA-E, both constitutively and because of
IFN-γ treatment.
The observation that protection occurred in a minority (10%-20%)
of the tested E/T combinations is reminiscent of the bare minority of
HLA-A2–restricted CTL clones to melanoma cells in which NKG2A-
mediated inhibition is detectable [16] and is not surprising, given the
many differences in lineage, genetic background, and intrinsic suscep-
tibility to lysis among tumor targets. Most likely, a redundancy in ac-
tivating and inhibitory ligand-receptor interactions masks or quenches
the specific contribution of HLA-E in certain tumor-NK and tumor-
CTL lytic combinations. Experiments (Figure 5) in which the inhibi-
tory role of NKG2A could be appreciated only upon block of activating
NK receptors (DNAM-1 and/or NCRs and/or NKG2D) provide evi-
dence in support of this interpretation.
Figure 5. Block of activating receptors reveals NKG2A-mediated
protection from NK lysis. The indicated tumor cell lines were tested
as targets in a 51Cr release assay using CD56+/CD3− cells as ef-
fectors, in the presence of the indicated antibodies. Blocking anti-
bodies to activating receptors were selected on the basis of the
ligands expressed by the target: A431 (DNAM-1), End7 (NKG2D +
DNAM-1), SK-MEL 37 (DNAM-1), andOva7 (NKG2D+DNAM-1). Dif-
ferences in 51Cr release values were statistically significant when
the average values of triplicates differed from control more than
three times the SD, that is, at E/T ratios from 20:1 to 2.5:1 in A431:
donor 1 as well as End7:donor 1 and at E/T ratios of 20:1 and 10:1 in
A431:donor 3. The top two panels display two E/T combinations
in which the inhibitory effect of NKG2A becomes evident only when
activating receptors are antibody-blocked. End7:donor 1 exemplifies
a case in which NKG2A similarly protects in the presence and
absence of antibody block. In the remaining cases, activating recep-
tors and NKG2A cannot be demonstrated to influence susceptibility
to lysis.
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A Model for the Regulation and Function of HLA-E in Tumors
There is evidence that HLA-E may favor both tumor escape and
tumor immune surveillance. Tumor escape is supported by a nega-
tive prognostic association of HLA-E expression in colorectal and
breast carcinomas [36,37]. A possible mechanism has been suggested
by at least two groups [14,36]. In this model, selective loss of HLA-A,
-B, and -C alleles (a phenotype proposed by some to be frequently
associated with immune evasion) alleviates competition for β2m, al-
lowing ligand donation from the residual class I allele(s) in amounts suf-
ficient to stabilize HLA-E, enhance its surface expression, engage the
inhibitory NKG2A receptor, and further promote immune escape.
However, three lines of evidence argue against the previously men-
tioned model and a purely negative role of HLA-E on survival: 1)
although HLA-E may have a low affinity for β2m in defined model sys-
tems [34], there is a subset of HLA-E molecules that efficiently binds
β2m [17]; 2) HLA-E is widely expressed in human tumors, as shown
herein; and 3) high HLA-E seems to correlate with good, and not poor,
prognosis in melanoma and glioblastoma [38–40].
By providing evidence that HLA-E is a widespread tumor recogni-
tion structure enabling NK cell recognition and monitoring, the pres-
ent study suggests that HLA-E might represent in at least some tumors
a very efficient checkpoint and failsafe mechanism against all kinds of
HLA losses and not a vulnerable soft spot toward immune evasion in
tumor mutants that have already accumulated multiple HLA defects.
It will be of interest to determine whether HLA-E on the tumor
cell surface engages rearranging and nonrearranging receptors, either
activating or inhibitory, expressed on different populations of NK,
CTL, and NK-CTL effectors, and whether it modulates immune
lysis. The applicable importance of HLA-E in tumor immunology re-
mains to be precisely addressed on the clonal level and in the context
of a global appreciation of the immune ligand–receptor network.
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Supplemental Materials and Methods
Immunohistochemistry
Samples were snap frozen in liquid nitrogen and stored at −80°C.
Four-micrometer cryostat sections were fixed in cold absolute acetone
for 10 minutes and either immediately used for indirect immuno-
peroxidase or stored at −20°C up to 6 months with no appreciable
changes in reactivity. Slides were incubated overnight with antibodies
(50 μg/ml) at 4°C in a moistened chamber. Control sections were in-
cubated with isotype-matched IgG. An indirect avidin-biotin immuno-
peroxidase staining was performed with commercially available reagents
(VECTASTAIN Elite, Mountain View, CA), and the enzymatic activ-
ity was developed using 3-amino-9-ethylcarbazole as the chromogenic
substrate for 8 minutes. Slices were then rinsed with phosphate-buffered
saline, counterstained with Mayer hematoxylin, and mounted with
buffered glycerol. At least three nonconsecutive sections from each spec-
imen were analyzed. Normal tissues were from at least two patients and
were collected distal to transformed tissues.
Cell Lines
JY and BSM are EBV-immortalized cell lines. Tumor cell lines
are listed along with their lineage and HLA-A, -B, and -C typing [1–
8]: Molt 4 (T lymphoblastoid; A1, 25; B18, 57; Cw6, 12), Jurkat
(T lymphoblastoid; A3; B35), WI-L2 (B lymphoblastoid; A1, 2;
B51, 17), Raji (B lymphoblastoid; A3), U937 (myelomonocytic; A3,
19; B51, 18; Cw1, 3), HL-60 (myelomonocytic; A10; B57; Cw6),
K562 (erythromyeloid; A11, 31; B18, 40; Cw3), Colo 38 (melanoma;
A24, 11; B35, 15; Cw3, 4), SK-MEL-37 (melanoma; A2, 11; B15, 55;
Cw1), SK-MEL-93 (melanoma; A2, 31; B21, 35; Cw4), FO-1 and its
β2m transfectant FO-1-β2m (melanoma; A25; B8; Cw7), A549 (carci-
noma; A25, 30; B18, 44; Cw12, 16), BT20 (carcinoma; A24; B15;
Cw3, 12), Calu-1 (carcinoma; A2, B40, 41; Cw2, 17), End 9 (carci-
noma; A24, 25; B15, 52; Cw1, 3), HT-29 (carcinoma; A1, 24; B35,
44; Cw4), MCF7 (carcinoma; A2, B18, 44; Cw5), T24 (carcinoma;
A1; B18; Cw5), HeLa (carcinoma; A68; B15; Cw16), KJ29 (carci-
noma; A2; B27; Cw1), and JAR (choriocarcinoma). Early passage
cell lines are melanoma Mel20 (A1, 31; B14, 18), ovarian carcinoma
Ova7 (A1, 11; B14, 51), endometrial carcinoma End7, and breast
carcinoma Br7.
As shown in Table W3 (representative results are shown in Fig-
ure W2), all the antibodies with nominal HLA-E specificity detected
HLA-E on the surface of 221.AEH transfectants overexpressing a
hybrid HLA-E heavy chain capable of self (in cis) ligand donation
[9], but they failed to detect levels of HLA-E exceeding twice the back-
ground in all the other tested cell lines. These include parental 221 cells
(expressing HLA-E but lacking HLA-A, -B, and -C and HLA-G), the
221.G1 and 221.B7 transfectants coexpressing “permissive” alleles,
and four EBV-immortalized, nontransformed B lymphoid cell lines
previously shown to synthesize from intermediate to high levels of
HLA-E [10].
Some of the listed tumor cell lines have previously been tested
by others [7,11]: U937 and Jurkat (3D12-positive), Raji (3D12-
negative), BT-20 and HT-29 (negative for MEM-E/06, MEM-E/
07, and MEM-E/08), Calu 1, A549, and K562 (negative for 3D12
and the three MEM antibodies as well), and MCF-7 (negative for
the MEM antibodies except MEM-E/07).
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Table W1. Distribution of MEM-E/02–Reactive HLA-E Heavy Chains in Normal Adult Tissues.
Unreactive Brain, retina, breast, bronchi, epidermis-adnexa, kidney, liver, lung, ovary,
peripheral nerves, prostate, skeletal and smooth muscle, stomach, testis,
thyroid, urether, urinary bladder
Reactive Decidual cells, endometrium, epididymis (principal but not basal cells),
Kupffer cells, pancreatic ducts, colon-rectum, vascular endothelial cells in
parotid, myometrium, pancreas, celomic epithelium, and chorionic villi
Table W2. Expression of MEM-E/02–Reactive HLA-E Heavy Chains in Nonlymphoid Tumors.
Tumor Origin Positive Histotype(s)
Brain 1/13* Pilocytic astrocytoma
Breast 4/17 Infiltrating ductal carcinoma
Colon rectum 7/20 Poorly (1)† and medium-
(6) differentiated adenocarcinoma
(various stages)
Endometrium 7/12 Well- (1) and medium-
(6) differentiated adenocarcinoma
Kidney 3/10 Papillary adenocarcinoma
Liver 1/6 Trabecular adenocarcinoma
Lung 11/20 Squamous carcinoma (4),
adenocarcinoma (7)
Melanoma (primary) 4/7 Primary lesions (various degrees of
dermal invasion)
Melanoma (metastatic) 13/32
Ovary 9/16 Serous (5) and endometrioid
(4) adenocarcinoma
Pancreas 1/5 Well-differentiated adenocarcinoma
Parotid 1/3 Squamous carcinoma
Skin 1/10 Squamous carcinoma
Soft tissues 7/21 Alveolar rhabdomyosarcoma (1),
hemangioendothelioma (1),

















Figure W1. Western blot analysis of neoplastic cell lines. Equal amounts (100 μg per lane) of soluble extracts from the indicated cell
lines were run on a SDS-PAGE (10% acrylamide) slab under reducing conditions and electroblotted. Two strips of the filter were stained
with MEM-E/02 and a polyclonal antibody to ERp57, respectively. HLA-E accumulation was largely independent from lineage and levels
of coexpressed HLA-A, -B, and -C molecules, assessed in a previous study on the same panel [12].
Figure W2. Flow cytometry analysis of the reactivity of MEM-E/02, MEM-E/06, MEM-E/07, MEM-E/08, 3D12 and 4D12. Cell lines (for a
complete list and a synopsis see Table W3) were tested for surface reactivity with the MEM antibodies, 3D12, 4D12, and W6/32, as a
control. Bound fluorescence was analyzed on a FACScan (Becton, Dickinson & Co). Staining with an isotype-matched (IgG1), irrelevant
antibody is shown (−). Each cell line was tested three to five times.
Table W3. Flow Cytometry Analysis of HLA-E Cell Surface Expression with the MEM Antibodies,
3D12 and 4D12*.
Cell Lines W6/32 MEM-E 3D12 4D12
/02 /06 /07 /08
221 and transfectants 221 30† 7 3 3 4 2 2
221.AEH 213 NT‡ 20 31 38 25 11
221.G1 206 4 4 4 3 4 4
221.B7 73 0 5 1 1 2 2
EBV-B cells BSM 252 5 1 2 2 NT NT
LG2 179 5 2 5 5 NT NT
MGAR 364 4 4 4 7 NT NT
JY 97 2 2 1 2 2 2
Lymphoblastoid cells Molt 4 61 3 2 2 1 NT NT
Jurkat 124 3 4 3 2 2 2
WI-L2 149 1 2 0 0 NT NT
U937 292 1 3 3 1 4 2
Raji 88 3 2 2 1 3 2
K562 17 1 1 1 1 NT NT
Melanoma cells Colo 38 75 0 0 1 2 NT NT
FO-1 3 2 0 2 1 NT NT
FO-1-β2m 85 0 1 1 1 0 0
HO-1 41 1 1 1 1 0 0
IR8 62 0 1 0 1 NT NT
M10 42 0 1 0 0 1 1
MNT-1 141 0 0 0 2 NT NT
SK-MEL-37 56 0 0 1 1 5 2
SK-MEL-93 182 1 1 1 1 NT NT
Carcinoma cells A431 81 0 1 2 2 1 1
A549 111 2 2 1 0 NT NT
BT20 14 0 2 0 0 NT NT
Calu-1 93 1 2 2 3 0 5
End 9 9 1 0 0 1 NT NT
H494 44 1 2 2 1 NT NT
HT-29 32 8 1 2 2 NT NT
JAR 6 1 3 3 2 NT NT
KJ29-β2m 179 2 2 5 4 NT NT
MCF7 10 0 2 1 4 0 0
T24 31 1 3 1 2 NT NT
*Representative results of this analysis are shown in Figure W2.
†All the values are expressed as specific mean fluorescence intensity (MFI) after background sub-
traction. Background values (invariably <9) were calculated by staining in parallel with irrelevant anti-
bodies of the IgG1 and IgG2a isotypes. SpecificMFI values represent themean of three to five separate
flow cytometry determinations.
‡Not tested.
Figure W3. HLA-E expression on surface of early passage tumor
cell lines. NP40 extracts from surface biotin-labeling experiments
performed as described in Figure 2 were blotted with the indicated
antibodies. The arrowhead marks residual staining by MEM-E/02
not removed by stripping.
Figure W4. Cytotoxic activity of NKL effectors against 221 target
cells. 221 and 221.AEH target cells were tested in parallel, at the
indicated E/T ratios, for their susceptibility to NK lysis in a conven-
tional 4-hour 51Cr release assay, using the same seed of NKL cells
as effectors, in the absence and presence of the indicated anti-
bodies or F(ab)2 fragments. A representative experiment is shown
of six that were performed.
Figure W5. Cytotoxic activity of NKL cells against tumor cells. NKL
cells were tested for their ability to lyse the indicated targets in
a 51Cr release assay, in the presence of the indicated antibodies
(C218 to CD56, GHI/75 to ILT2, and Z199 to NKG2A). Lytic enhance-
ments by GHI/75 and Z199 were statistically significant when the
average values of triplicates differed from control more than three
times the SD, that is, at E/T ratios from 20:1 to 2.5:1 in FO-1-β2m
and at E/T ratios of 20:1 and 10:1 in A431. All the cell lines were
tested three times.
Figure W6. Flow cytometry analysis of polyclonal NK cells. NK cells
obtained by negative immunomagnetic selection were submitted
to two-color flow cytometry using an fluorescence isothiocyanate–
labeled antibody to CD56 (MOC-1), displayed in abscissa, and PE-
labeled antibodies to CD3 (UCHT1), NKG2A (131411), NKG2C
(134591), NKG2D (149810), KIR2DL1/DS1 (11PB6), KIR3DL1 (DX9),
KIR2DL2/DL3 (DX27), ILT2 (GHI/75), NKG2A (131411), NKG2C
(134591), NKG2D (149810), DNAM-1 (102511), NKp30 (210845),
NKp44 (253415), and NKp46 (195314), displayed in ordinates. A
combination of fluorescence isothiocyanate–labeled and PE-labeled
isotype-specific controls is shown in the upper right panel. NK cells
expanded in culture display a homogeneous CD56 staining intensity
that appears to be slightly higher than that of the bulk CD56dim NK
cell populations freshly obtained from the PBMCs of two donors
before culturing. A slight but consistent enhancement of ILT2,
NKG2A, NKG2C, and NKG2D receptors (particularly of NKG2A)
was also noted. Receptor expression patterns were similar in all
the tested donors with the exception of a variable KIR expression.
Among NCRs, NKp30 was consistently less expressed.
Table W4. Expression* of Ligands of Activating NK Receptors by Selected Tumor Cell Lines.
Antibodies Ig-fusion
MICA MICB ULBP1 ULBP2 ULBP3 PVR Nectin-2 p30-Ig p44-Ig p46-Ig DNAM-1-Ig
Raji 11 1 0 0 0 0 0 0 0 0 1
WI-L2 0 4 0 0 0 0 0 0 1 1 0
A431 10 1 3 8 0 75 0 0 0 0 10
FO-1-β2m 41 2 0 10 0 161 6 15 6 6 25
SK-MEL-37 0 3 0 0 2 145 0 0 0 0 19
Mel20 0 0 0 19 0 52 0 0 0 0 7
Ova7 14 0 1 22 2 85 11 0 17 0 55
End7 0 0 2 30 6 150 14 0 0 0 36
Br7 12 1 0 27 5 43 22 0 0 0 30
*Specific MFI following background subtraction.
Surface expression of the ligands of major activating NK receptors NKG2D, DNAM-1, NKp30, NKp44, and NKp46. NKG2D ligands, namely, the MHC class I chain-related antigen A and B (MICA/
B), and UL16 binding proteins 1 to 3 (ULBP1-3), were tested by specific antibodies. DNAM-1 ligands were assessed by antibodies to the polyovirus receptor (PVR, CD155) and Nectin-2 (CD112), as
well as a chimeric receptor-Ig fusion protein. NKp30, NKp44, and NKp46 ligands were assessed by the respective chimeric Ig-fusion proteins. MFI values greater than 11 and greater than 5 for antibody
and Ig-fusion proteins (boldface) are considered positive.
